Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

@article{Coombes2007SurvivalAS,
  title={Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial},
  author={R. Coombes and L. Kilburn and C. Snowdon and R. Paridaens and on behalf of the Intergroup Exemestane Study},
  journal={The Lancet},
  year={2007},
  volume={369},
  pages={559-570}
}
  • R. Coombes, L. Kilburn, +2 authors on behalf of the Intergroup Exemestane Study
  • Published 2007
  • Medicine
  • The Lancet
  • BACKGROUND Early improvements in disease-free survival have been noted when an aromatase inhibitor is given either instead of or sequentially after tamoxifen in postmenopausal women with oestrogen-receptor-positive early breast cancer. However, little information exists on the long-term effects of aromatase inhibitors after treatment, and whether these early improvements lead to real gains in survival. METHODS 4724 postmenopausal patients with unilateral invasive, oestrogen-receptor-positive… CONTINUE READING
    785 Citations

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using exemestane or tamoxifen may fight breast cancer by blocking the uptake of estrogen. It is not… Expand
    ConditionsBreast Cancer
    InterventionDrug
    Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
    • 279
    Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen
    • 36
    • Highly Influenced
    Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
    • 176

    References

    SHOWING 1-10 OF 24 REFERENCES
    Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    • 434
    • PDF
    Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    • 828